biote Corp.BTMD

Biote Corp.-the outfit behind hormone-optimised pellets and a growing shelf of nutraceuticals-posted $44.9 million of revenue and $2.3 million of net income for the quarter ended 31 March 2026, results buried in a 10-Q filed on 11 May. That top line is up from the same quarter last year, but the company’s $89 million of total assets are matched by $137 million of liabilities, giving shareholders a $56.1 million deficit and just $5.3 million in cash.

Biote sells hormone-therapy products and companion supplements online and through clinics, pitching “bioidentical hormone replacement therapy” alongside daily iodine and NAD+ capsules designed to “go hand-in-hand” with pellet insertion. The product pages boast of clinically validated approaches and cite decades of scientific insight, but the latest 10-Q lists no formal clinical read-outs and no customer accounting for more than 10% of revenue in the quarter. The company’s inventory, meanwhile, sits at $19.9 million-mostly nutraceuticals and packaging-while the cash-flow line shows $3.9 million of operating cash inflow and a modest $362k of capex.

Filings since mid-May reveal a revolving door of 8-K disclosures: on 2 June the company disclosed the departure of a senior executive under a “without cause” severance clause; on 17 June it filed an amended 8-K clarifying the payout mechanics; and on 10 June it issued four separate 8-Ks related to director elections and share issuance. The XBRL facts show diluted EPS of $0.06 on 36 million shares, a figure so small it reads like rounding error against the $137 million liability stack.

The company’s press centre trumpets “over 80 years of scientific insight” and links to a research page that promises to bridge “the wide gap that exists in formal clinical research and education,” yet the latest 10-Q contains no pivotal trial data or FDA approvals, and the product page itself stops short of publishing peer-reviewed outcomes. The official site does, however, host product images and press materials, confirming a real shelf of retail-ready supplements rather than a pipeline of regulated therapies.

There is no disclosed guidance, no dividend policy, and no share-buyback programme in the filings. The absence of single-customer concentration suggests a fragmented retail channel, while the $19.9 million inventory build implies either aggressive stocking or thin sell-through. Without a clear clinical or regulatory catalyst, the current tension is the gap between polished product storytelling and the thin, concentrated balance sheet that actually funds it.